Robbins LLP Is Investigating the Officers and Directors of Poseida Therapeutics, Inc.  (PSTX) on Behalf of Shareholders

Poseida conducted its IPO on July 10, 2020, issuing 14 million shares for $16.00 per share.  On August 18, 2020, Poseida announced that the U.S. Food and Drug Administration had placed a clinical hold on its Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer due to a patient's death.  On this news, Poseida's stock fell 30.31%, to close at $9.06 on August 18, 2020.